Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis
2011 · Graefe s Archive for Clinical and Experimental Ophthalmology · 181 citations
https://doi.org/10.1007/s00417-011-1844-0
R
Rémy L.M. Mostard
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
95
Papers
2.0K
Citations
23
h-index
31
i10-index
Rémy L.M. Mostard is an academic researcher from Maastricht University Medical Centre. The author has contributed to research in topics: Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis & Sarcoidosis and Beryllium Toxicity Research & COVID-19 Clinical Research Studies. The author has an h-index of 23, co-authored 81 publications.
ORCID: 0000-0002-0127-2855Papers by this author
worksZiritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis
2023 · JAMA · 103 citations
https://doi.org/10.1001/jama.2023.5355
Design of a randomized controlled trial to evaluate effectiveness of methotrexate versus prednisone as first-line treatment for pulmonary sarcoidosis: the PREDMETH study
2020 · BMC Pulmonary Medicine · 46 citations
https://doi.org/10.1186/s12890-020-01290-9
Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study
2020 · Respiratory Research · 30 citations
https://doi.org/10.1186/s12931-020-01458-1
Pulmonary embolism in hospitalized COVID-19 patients: Short- and long-term clinical outcomes
2023 · Thrombosis Update · 2 citations
https://doi.org/10.1016/j.tru.2023.100142
Correlation Between Methotrexate Polyglutamates Concentrations in Red Blood Cells and Pulmonary Function in Patients Treated With Methotrexate in the PREDMETH Trial
2025 · American Journal of Respiratory and Critical Care Medicine · 0 citations
https://doi.org/10.1164/ajrccm.2025.211.abstracts.a7643
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat